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provide a more precise prognostication of survival for patients 
with OCSCC compared to TNM staging. Further investigation of 
these prognostic roles is merited to allow individual patient risk-
stratification and may help in treatment decision and trial 
design. 
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IS A SHIFT IN THE STANDARD OF CARE CHEMOTHERAPY FOR 
PATIENTS WITH ESOPHAGEAL CANCER PRE-MATURE?  
Xuan Lu Qu, Lisa Tremblay, Aamer Mahmud 
Queen's University, Kingston, ON 
Purpose: To compare outcomes among patients with localized 
esophageal and gastro-esophageal junction (GEJ) cancer who 
received concomitant chemo-radiation (CRT) using either 
cisplatin/5-FU or carboplatin/paclitaxel. CROSS 
trial demonstrated efficacy of carboplatin/paclitaxel in tri-
modality setting. However this regimen has also been 
adopted as an alternate for patients receiving CRT as 
definitive treatment due to better tolerance. 
Methods and Materials: Medical records of all patients diagnosed 
with localized carcinoma of esophagus and GEJ who underwent 
definitive CRT using cisplatin/5-FU, carboplatin/5-FU, or 
carboplatin/paclitaxel between January 2008 and March 2015 at 
our academic centre were reviewed. 
Results: Seventy-five patients (79% male) were identified with a 
median age of 74 years (range 45-86). Most (66%) had an 
adenocarcinoma and 37% squamous cell carcinoma. Sixty-three 
percent had distal 1/3rd and/or GEJ tumour. 48% received 
cisplatin/5-FU, 35% carboplatin/paclitaxel and 17% 
carboplatin/5-FU. Most patients (99%) received 50Gy in 25 
fractions. The median overall survival (OS) for cisplatin/5-FU 
group was 27 months (m) (95%CI 17-39) with three-year OS of 
42%, in contrast to 14 m (95%CI 11-17) and 13% among patients 
received carboplatin/paclitaxel (log-rank p = 0.006). The median 
OS for carboplatin/5-FU group was 17 m (95%CI 11-81) with 
three-year OS of 38%. Cisplatin/ 5-FU group had a significantly 
better distant metastasis free survival (median 20 versus 11 m, 
p = 0.04) when compared to carboplatin/paclitaxel group. On 
multivariate analysis, cisplatin/5-FU (hazard ratio(HR) 0.45, p = 
0.023) and carboplatin/5-FU group (HR 0.46, p = 0.093) were 
found to be associated with OS adjusted for other patient, 
disease and treatment related characteristics. 
Conclusions: We report that patients receiving cisplatin/5-FU 
had a significant survival benefit compared to patients who 
received carboplatin/paclitaxel as a definitive treatment for 
esophageal and GEJ cancer. Carboplatin/ 5FU might be a 
reasonable alternate for highly select patients. Clinical trials 
regarding optimal chemotherapy regimen are warranted for 
patients who are not surgical candidates. 
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PLANNED VERSUS ‘DELIVERED’ BLADDER DOSE RECONSTRUCTED 
USING SOLID AND HOLLOW ORGAN MODELS DURING PROSTATE 
CANCER IMRT  
Tara Rosewall1, Janelle Wheat2, Geoffrey Currie2, Vickie Kong1, 
Andrew Bayley1, Joanne Moseley1, Peter Chung1, Charles 
Catton1, Tim Craig1, Michael Milosevic1 
1Princess Margaret Cancer Centre, Toronto, ON 
2Charles Sturt University, Wagga Wagga, New South Wales, 
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Purpose: All studies to date have evaluated the dosimetric effect 
of bladder deformation using an organ model that includes the 
dose to the urine. This research reconstructed bladder dose using 
both hollow and solid organ models, to determine if dose/volume 
differences exist. 
Methods and Materials: Thirty-five prostate IMRT patients were 
selected, who had received 78 Gy in 39 fractions and full bladder 
instructions. Biomechanical modeling and finite element analysis 
was used to reconstruct bladder dose (solid and hollow organ 
model) using every third CBCT throughout the treatment course. 
Results: Reconstructed bladder dose was 11.3 Gy greater than 
the planned dose with a hollow model (p < 0.001) and 12.3Gy 
greater with a solid model (p < 0.0001). Median reconstructed 
volumes within the 30 Gy, 65 Gy and 78 Gy isodoses were 3-4 
times larger with the solid bladder model (p < 0.0001). Using a 
solid bladder model resulted in a difference between planned 
and reconstructed dose that was 10% larger than when using a 
hollow model. The difference between planning bladder volume 
and median treatment volume was associated with the 
difference between the planned and reconstructed dose below 
78 Gy (R2 > 0.61). 
Conclusions: Substantial differences exist between planned and 
reconstructed bladder dose, associated with the differences in 
bladder filling between planning and treatment. Dose 
reconstructed using a solid bladder model over-reports the 
volume of bladder within key isodose levels and overestimates 
the differences between planned and reconstructed dose. Dose 
reconstruction with a hollow organ model is recommended if the 
goal is to associate that dose with toxicity. 
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LATE TOXICITY AFTER TBI IN AHCT FOR RELAPSED FOLLICULAR 
LYMPHOMA  
Steven Tisseverasinghe1, Rajiv Samant1, Mitchell Sabloff1, Yuhui 
Xu2, Christopher Bredeson1, Lothar Huebsch1, Paul Genest1 
1University of Ottawa, Ottawa, ON 
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Purpose: Follicular lymphoma (FL) is a progressive relapsing 
hematologic malignancy. At The Ottawa Hospital (TOH), 
autologous hematopoietic cell transplantation (AHCT) utilizing 
total body irradiation (TBI) has been used to treat relapsed FL 
patients for over 20 years. We reviewed our large single 
institution experience and assessed outcomes and late toxicity. 
Methods and Materials: We retrospectively reviewed 
consecutive patients undergoing AHCT for relapsed FL from July 
1991 to February 2013. The pre-AHCT conditioning regimen was 
commonly Etoposide/Melphalan/TBI. Patients received TBI on a 
linear accelerator using a translating-bed technique. The total 
dose was 5 Gy/1fr for 92% of patients, the remainder received 
12Gy/6fr. Lung attenuators were used to maintain dose 
homogeneity. Patient information was stored on our bone 
marrow transplant (BMT) database. Descriptive statistics were 
calculated for all relevant demographic variables. Overall 
survival was estimated from the BMT date using the Kaplan-Meier 
method. Second malignancies were reported. Late toxicity was 
assessed in patients with at least one year of follow up (FU). 
Lung, kidney and thyroid toxicity was evaluated through 
extensive chart reviews. Clinical toxicity, creatinine, PFTs, chest 
imaging, thyroid function tests were assessed pre-AHCT and 
post-AHCT. 
Results: We evaluated 174 patients with a median age of 50 years 
at transplant. There were 106 men and 68 women. Median follow 
up was 6.0 years. Median follow up among survivors was 8.3 
years. Overall survival at one, five, 10 and 15 years was 93%, 
73%, 57% and 47% respectively. Eighteen patients (10.3 %) 
developed a second malignancy; 11 (6.3%) had solid tumours, two 
(1.1%) had AML and five (2.9%) developed myelodysplastic 
syndrome. Median time to second malignancy was 7.2 years, with 
cumulative incidences of developing second cancer at 5% and 8% 
at five and 10 years. We evaluated 149 patients with at least one 
year of follow up. Of 80 assessable patients, 23% developed 
hypothyroidism; 3% were hypothyroid beforehand. Pre-AHCT, 
creatinine ranged from 41 to 139 umol/L. Post AHCT, at last FU, 
of 116 patients, creatinine (umol/L) was < 100 in 63%, 100-150 
in 20%, 151-200 in 6% and > 200 in 9%. Hemodialysis was required 
for two patients. Clinical lung toxicity was noted in 6% of 95 
patients. PFTs were recorded in 26 patients pre-AHCT and 46 
patients post-AHCT. Abnormalities in DLCO were noted in 17% 
pre-AHCT and 26% of post-AHCT. Abnormalities in FEV1 were 
noted in 11% pre-AHCT and 25% of post-AHCT. Radiologic 
abnormalities were noted in 39%, with 23% being fibrotic 
changes, possibly radiation-induced, and 17% likely unrelated. 
Conclusions: Our results with TBI-based AHCT for relapsed FL are 
very good, with most patients surviving 10 years post-AHCT. 
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Severe late toxicity involving the lungs, kidneys and thyroid was 
relatively low. The risk of second cancers was acceptable. Our 
study indicates that this approach is both safe and effective. 
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A 3D OPTICAL SCANNER FOR IMAGE ACQUISITION IN 3D PRINTING- 
OPTIMIZING IMAGE ACCURACY THROUGH THE DEVELOPMENT OF 
AN IN-HOUSE DESIGNED GANTRY  
Kate Johnson1, Arbind Dubey1, Chad Harris2, David Sasaki1, Andy 
Egtberts2, Daniel Rickey1, Rashmi Koul2 
1University of Manitoba, Winnipeg, MB 
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Purpose: The use of 3D printing for medical use is well 
established and has been utilized in clinical practices ranging 
from surgical planning to individualized medical implants. Three-
dimensional printing has been implemented at our institution to 
create customized treatment accessories such as shielding and 
immobilization. In order to use 3D printing, the topography of 
the patient must first be acquired. We have previously achieved 
this using resource intensive methods such as a plaster mould or 
a CT scan. Recently, 3D scanners have been developed which are 
low cost (~$500), and can quickly acquire both the topographical 
and texture information of a patient. These scanners use 
methods such as structured light in order to construct accurate 
3D models in minutes. We have characterized a structured light 
3D scanner (3D Systems Sense), and have designed and built a 
scanning gantry in order to assess the clinical viability of this 
technology. 
Methods and Materials: The gantry consists of a circular hoop 
formed from square aluminum tubing, with a diameter of 126.5 
cm. The optical scanner is mounted to an arm that can be moved 
isocentrically along the circumference of the hoop. The scanner-
to-surface distance is adjustable to accommodate differently 
sized regions of the body. The gantry can tilt with respect to the 
patient table, allowing for acquisition of topography from 
virtually any direction. The gantry was built in-house with a total 
cost of about $500. 
An anthropomorphic head phantom was used to quantify the 
accuracy of the gantry-mounted 3D scanner. Meshes acquired 
using the 3D scanner were compared to a mesh generated from 
a high resolution CT scan, which was taken to be the gold 
standard. Optimal scan settings were identified and final 
assessment of the accuracy of the scanner was quantified using 
the Hausdorff distance between the two meshes. 
Results: The in-house gantry enabled quick and easy acquisition 
of patient topographical information with a low cost 3D scanner. 
Acquisition was much easier than using the scanner free-hand. 
The mean Hausdorff distance was typically found to be less than 
0.5 mm, with maximum errors in the range of 1-2 mm. This was 
deemed to be clinically acceptable and the scanner has been 
used to design treatment accessories for several skin cancer 
patients. 
Conclusions: Through a collaborative and innovative approach, 
an optical scanner gantry has been developed which can quickly, 
easily and accurately acquire topographical information. This 
information can then be used to design customized treatment 
accessories for many different treatment sites and modalities, 
including bolus and immobilization for both photon and electron 
treatments and shielding for orthovoltage treatments. The 
gantry is very lightweight and easy to store. 
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CAN VMAT IMPROVE CONFORMALITY WHILE MAINTAINING KIDNEY 
DOSE FOR SEMINOMA PATIENTS  
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Purpose: To evaluate the use of VMAT planning techniques for 
para-aortic and ipsilateral pelvic irradiation in seminoma 
patients, driven by standard kidney contours and automatically 
generated concentric rings about the PTV. 
Material and Methods: Ten seminoma patients with small 
volume retroperitoneal nodes (< 5 cm) were randomly selected. 
CTV2 included the gross tumour plus a 5 mm margin, and CTV1 
was contoured based on an expansion of blood vessels. PTV was 
defined by addition of 5 mm margin around the corresponding 
CTV, with PTV1 extending from 2 cm below the top of kidney to 
the top of femoral head, and modified to exclude both kidneys. 
The prescription dose (in 20 fractions) was 25 and 35 Gy for PTV1 
and PTV2 respectively. Abdominal and pelvic organs at risk (OAR) 
were contoured. For each patient, a conformal (AP-PA, 18 MV) 
and VMAT (two 360-degree coplanar arcs, six MV, 15-degree 
collimator twist) plans were created. Dose constraints for the 
VMAT optimization were: Rt and Lt Kidney (D50% <350 cGy, max 
EUD < 350 cGy); RingPTV+2 cm (max dose = PTVmin), Normal 
tissue 4 cm beyond PTV (max dose < 1000 cGy, D50% < 150 cGy, 
D20% < 500 cGy). No other structures were included in the 
optimization. The maximum (D2%), mean (D50%) and minimum 
dose (D98%) for PTVs and OAR were obtained and compared 
between plans. 
Results: There was no difference in the coverage of PTV2, while 
VMAT provided better PTV1 coverage: mean D98% was 24.2 Gy 
+/- 0.16 versus 23.9 Gy +/- 0.25 (p = 0.05). Use of VMAT reduced 
the volume of normal tissue receiving 95% of the prescribed dose 
from 11% to 2%, compared to the conformal AP-PA plans (p = 
0.005). Kidney D2% was reduced by 6Gy with VMAT (p = 0.03), 
while the kidney D50% was 1.3 Gy higher (p = 0.01). There was 
no significant difference in D2% or D50% for either heart or 
pancreas. VMAT reduced spinal cord dose: D2% (28.2 Gy +/- 2.2 
versus 32.2 Gy +/-4.4, p = 0.02) and D50% (12.6 Gy +/- 8.7 versus 
19.8 Gy +/- 7.4, p = 0.01), and reduced the D2% for bone marrow 
(p = 0.01), large bowel (p = 0.05) and stomach (p = 0.05) but not 
for bladder or liver. Conversely, the conformal APPA resulted in 
lower D50% to bone marrow (p = 0.01), large bowel (p = 0.05), 
stomach (p = 0.01), bladder (p = 0.05) and liver (p = 0.05). 
Conclusions: It is possible to generate organ-sparing VMAT plans 
with only the kidneys and automatically generated concentric 
PTV rings included in the optimization process. Use of VMAT for 
para-aortic/pelvic irradiation improves the conformality of the 
isodoses to the PTV and reduces the maximum dose to the 
surrounding OAR, but at the cost of an increase in the low dose 
region. 
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Purpose: Treatment of non-melanoma skin cancers of the face 
using ortho-voltage radiotherapy may require lead shielding to 
protect vulnerable organs at risk (OAR). As the human face has 
many complex and intricate contours, creating a lead shield can 
be difficult. The process can include creating a plaster mould of 
a patient’s face to create the shield. It can be difficult or 
impossible for a patient who is claustrophobic or medically 
unable to lie flat to have a shield made by this technique. Other 
methods have their own shortcomings. We aimed to address 
some of these issues using an optical scanner and 3D printer 
technology. 
Methods and Materials: The clinicians identified three patients 
with skin cancer involving the nose who required treatment with 
low energy photons and would benefit from lead shielding. 
Marking was made on these patients to define the field. Optical 
images of these patients were acquired using a consumer-grade 
optical scanner (3D Systems, Sense). A 3D model of each patient 
was processed with mesh editing software (Autodesk, MeshMixer 
v2.9) before being exported as an STL file to software controlling 
the printer (Repetier-Host). A positive model of each face was 
printed using polylactic acid on a consumer-Grade 3D printer 
